Kidney Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Class (Targetted Therapy, Immunotherapy); Pharmacologic Class (Angiogenesis Inhibitors, MTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)) and Geography

Report Code: TIPRE00003834 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

The term ""kidney cancer"" refers to cancer that begins in the kidneys. Renal cell carcinoma is the most prevalent type of kidney cancer, which usually develops as a single tumour within the kidney. Transitional cell carcinoma, Wilms tumour (nephroblastoma), renal sarcoma, renal adenomas, oncocytoma, and other types of kidney cancers. Kidney cancer is among the common types of cancers and is more prevalent in people above age of 60. Various treatment approaches such as, chemotherapy, radiation, surgery are available to treat kidney cancer.

MARKET SCOPE

The "Global Kidney Cancer Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Kidney cancer drugs market with detailed market segmentation by therapeutics class and pharmacologic class. The report provides key statistics on the market status of the leading Kidney cancer drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •   Based on therapeutic class the market is segmented as, targeted therapy and immunotherapy.
  •   Based on pharmacologic class the market is segmented as, angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (IL-2).

MARKET DYNAMICS
Drivers:

  •   Increasing prevalence of kidney cancers and other forms of renal carcinomas.
  •   Growing geriatric population across the globe.
  •   Presence of various risk factors such as, obesity, smoking, unhealthy lifestyles, blood pressure issues are also expected to spur the market growth.
  •   Extensive research and development activities to develop robust therapies for management of kidney cancers.
  •   Rising awareness and screening activities of cancers.

Restraints:

  •   However, high cost of therapies, poor reimbursement policies and chances of side effects from treatment are expected to restrain market growth during the forecast period.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Kidney cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Kidney cancer drugs market in these regions.

IMPACT OF COVID-19 ON KIDNEY CANCER DRUGS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for kidney cancer drugs and therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for kidney cancer therapeutics and drugs According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS

The report covers key developments in the Kidney cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Kidney cancer drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Kidney cancer drugs in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Kidney cancer drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Pfizer Inc.
  •   Novartis AG
  •   Bayer AG
  •   Genentech, Inc
  •   Bristol-Myers Squibb Company
  •   Exelixis, Inc.
  •   Eisai Inc
  •   Active Biotech AB
  •   GlaxoSmithKline plc
  •   F. Hoffmann-La Roche Ltd
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Kidney Cancer Drugs Market - By Therapeutic Class
1.3.2 Kidney Cancer Drugs Market - By Pharmacologic Class
1.3.3 Kidney Cancer Drugs Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. KIDNEY CANCER DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS

5. KIDNEY CANCER DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. KIDNEY CANCER DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. KIDNEY CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. KIDNEY CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. KIDNEY CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC CLASS
7.1. OVERVIEW
7.2. THERAPEUTIC CLASS MARKET FORECASTS AND ANALYSIS
7.3. TARGETTED THERAPY
7.3.1. Overview
7.3.2. Targetted Therapy Market Forecast and Analysis
7.4. IMMUNOTHERAPY
7.4.1. Overview
7.4.2. Immunotherapy Market Forecast and Analysis
8. KIDNEY CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - PHARMACOLOGIC CLASS
8.1. OVERVIEW
8.2. PHARMACOLOGIC CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANGIOGENESIS INHIBITORS
8.3.1. Overview
8.3.2. Angiogenesis Inhibitors Market Forecast and Analysis
8.4. MTOR INHIBITORS
8.4.1. Overview
8.4.2. mTOR Inhibitors Market Forecast and Analysis
8.5. MONOCLONAL ANTIBODIES
8.5.1. Overview
8.5.2. Monoclonal Antibodies Market Forecast and Analysis
8.6. CYTOKINE IMMUNOTHERAPY (IL-2)
8.6.1. Overview
8.6.2. Cytokine Immunotherapy (IL-2) Market Forecast and Analysis

9. KIDNEY CANCER DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Kidney Cancer Drugs Market Overview
9.1.2 North America Kidney Cancer Drugs Market Forecasts and Analysis
9.1.3 North America Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.1.4 North America Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.1.5 North America Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Kidney Cancer Drugs Market
9.1.5.1.1 United States Kidney Cancer Drugs Market by Therapeutic Class
9.1.5.1.2 United States Kidney Cancer Drugs Market by Pharmacologic Class
9.1.5.2 Canada Kidney Cancer Drugs Market
9.1.5.2.1 Canada Kidney Cancer Drugs Market by Therapeutic Class
9.1.5.2.2 Canada Kidney Cancer Drugs Market by Pharmacologic Class
9.1.5.3 Mexico Kidney Cancer Drugs Market
9.1.5.3.1 Mexico Kidney Cancer Drugs Market by Therapeutic Class
9.1.5.3.2 Mexico Kidney Cancer Drugs Market by Pharmacologic Class
9.2. EUROPE
9.2.1 Europe Kidney Cancer Drugs Market Overview
9.2.2 Europe Kidney Cancer Drugs Market Forecasts and Analysis
9.2.3 Europe Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.2.4 Europe Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.2.5 Europe Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Kidney Cancer Drugs Market
9.2.5.1.1 Germany Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.1.2 Germany Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.2 France Kidney Cancer Drugs Market
9.2.5.2.1 France Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.2.2 France Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.3 Italy Kidney Cancer Drugs Market
9.2.5.3.1 Italy Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.3.2 Italy Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.4 Spain Kidney Cancer Drugs Market
9.2.5.4.1 Spain Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.4.2 Spain Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.5 United Kingdom Kidney Cancer Drugs Market
9.2.5.5.1 United Kingdom Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.5.2 United Kingdom Kidney Cancer Drugs Market by Pharmacologic Class
9.2.5.6 Rest of Europe Kidney Cancer Drugs Market
9.2.5.6.1 Rest of Europe Kidney Cancer Drugs Market by Therapeutic Class
9.2.5.6.2 Rest of Europe Kidney Cancer Drugs Market by Pharmacologic Class
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Kidney Cancer Drugs Market Overview
9.3.2 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.3.4 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.3.5 Asia-Pacific Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Kidney Cancer Drugs Market
9.3.5.1.1 Australia Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.1.2 Australia Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.2 China Kidney Cancer Drugs Market
9.3.5.2.1 China Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.2.2 China Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.3 India Kidney Cancer Drugs Market
9.3.5.3.1 India Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.3.2 India Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.4 Japan Kidney Cancer Drugs Market
9.3.5.4.1 Japan Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.4.2 Japan Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.5 South Korea Kidney Cancer Drugs Market
9.3.5.5.1 South Korea Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.5.2 South Korea Kidney Cancer Drugs Market by Pharmacologic Class
9.3.5.6 Rest of Asia-Pacific Kidney Cancer Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Kidney Cancer Drugs Market by Therapeutic Class
9.3.5.6.2 Rest of Asia-Pacific Kidney Cancer Drugs Market by Pharmacologic Class
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Kidney Cancer Drugs Market Overview
9.4.2 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.4.4 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.4.5 Middle East and Africa Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Kidney Cancer Drugs Market
9.4.5.1.1 South Africa Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.1.2 South Africa Kidney Cancer Drugs Market by Pharmacologic Class
9.4.5.2 Saudi Arabia Kidney Cancer Drugs Market
9.4.5.2.1 Saudi Arabia Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.2.2 Saudi Arabia Kidney Cancer Drugs Market by Pharmacologic Class
9.4.5.3 U.A.E Kidney Cancer Drugs Market
9.4.5.3.1 U.A.E Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.3.2 U.A.E Kidney Cancer Drugs Market by Pharmacologic Class
9.4.5.4 Rest of Middle East and Africa Kidney Cancer Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Kidney Cancer Drugs Market by Therapeutic Class
9.4.5.4.2 Rest of Middle East and Africa Kidney Cancer Drugs Market by Pharmacologic Class
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Kidney Cancer Drugs Market Overview
9.5.2 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis
9.5.3 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis - By Therapeutic Class
9.5.4 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis - By Pharmacologic Class
9.5.5 South and Central America Kidney Cancer Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Kidney Cancer Drugs Market
9.5.5.1.1 Brazil Kidney Cancer Drugs Market by Therapeutic Class
9.5.5.1.2 Brazil Kidney Cancer Drugs Market by Pharmacologic Class
9.5.5.2 Argentina Kidney Cancer Drugs Market
9.5.5.2.1 Argentina Kidney Cancer Drugs Market by Therapeutic Class
9.5.5.2.2 Argentina Kidney Cancer Drugs Market by Pharmacologic Class
9.5.5.3 Rest of South and Central America Kidney Cancer Drugs Market
9.5.5.3.1 Rest of South and Central America Kidney Cancer Drugs Market by Therapeutic Class
9.5.5.3.2 Rest of South and Central America Kidney Cancer Drugs Market by Pharmacologic Class

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. KIDNEY CANCER DRUGS MARKET, KEY COMPANY PROFILES
11.1. PFIZER INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NOVARTIS AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BAYER AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GENENTECH, INC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB COMPANY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. EXELIXIS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. EISAI INC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. ACTIVE BIOTECH AB
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GLAXOSMITHKLINE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. F. HOFFMANN-LA ROCHE LTD
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
"
The List of Companies

- Pfizer Inc.
- Novartis AG
- Bayer AG
- Genentech, Inc
- Bristol-Myers Squibb Company
- Exelixis, Inc.
- Eisai Inc
- Active Biotech AB
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Amgen
- Merck Sharp and Dohme Corp
- AstraZeneca
TIPRE00003834
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking